Clincosm LogoSign in Get a demo

Safety and Efficacy Study of COV155 for Post-operative Bunionectomy Pain

Sponsor
Mallinckrodt (Industry)
Overall Status
Completed
CT.gov ID
NCT01743625
Collaborator
(none)
406
Enrollment
5
Locations
2
Arms
8
Duration (Months)
81.2
Patients Per Site
10.2
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

The purpose of this study is to show the effectiveness of COV155 compared to placebo in subjects with acute moderate to severe pain following bunionectomy surgery.

Condition or Disease Intervention/Treatment Phase
Phase 3

Study Design

Study Type:
Interventional
Actual Enrollment :
406 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Double (Participant, Investigator)
Primary Purpose:
Treatment
Official Title:
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-Controlled, Parallel-Group Evaluation of the Safety and Analgesic Efficacy of COV155 Tablets in Moderate to Severe Post-Operative Bunionectomy Pain Followed by an Open-Label Extension
Study Start Date :
Nov 1, 2012
Actual Primary Completion Date :
May 1, 2013
Actual Study Completion Date :
Jul 1, 2013

Arms and Interventions

Arm Intervention/Treatment
Experimental: COV155

COV155, loading dose of 3 tablets followed by 2 tablets every 12 hours for 48 hours.

Drug: COV155
COV155 tablets
Other Names:
  • MNK155

    		•
    Placebo Comparator: Placebo

    Matching tablet to COV155 without containing active ingredients, loading dose of 3 tablets followed by 2 tablets every 12 hours for 48 hours.

    Drug: placebo

    Outcome Measures

    Primary Outcome Measures

    1. SPID48 (Summed pain intensity difference) [48 hours]

      48 hour Summed pain intensity difference

    Secondary Outcome Measures

    1. Safety and tolerability of COV155 [48 hours]

      Safety and tolerability to be evaluated with physical exams, vital signs, pulse oximetry, clinical laboratory tests, electrocardiograms, and adverse events

    2. Onset of analgesia of COV155 versus placebo [48 hours]

      Onset of confirmed perceptible pain relief, time to meaningful pain relief, and time to peak pain intensity difference

    3. Analgesic effects of COV155 versus placebo [48 hours]

      Pain intensity scores, pain intensity differences, and summed pain intensity differences; pain relief scores and total pain relief; percent responders; mean dosing interval; use of rescue medication; global assessment of subject satisfaction with study treatment.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No

    Inclusion Criteria

    • Voluntarily provide written informed consent

    • General good health

    • 18 to 75 years of age

    • Scheduled for primary unilateral first metatarsal bunionectomy (with no collateral procedures)

    • Body mass index ≤33

    • Female subjects eligible if

    • Not pregnant or lactating; not planning to become pregnant for duration of study;

    • Surgically sterile, or have a monogamous partner who is surgically sterile, or at least 2 years postmenopausal, or practicing acceptable birth control for more than 2 months prior to Screening, during the study and for 1 week following last dose of COV155

    • Male subjects must be sterile (biologically or surgically) or use reliable birth control during the study until at least 1 week after the last dose of COV155

    • Classified as either Physical Status-1 (PS) or PS-2 by the American Society of Anesthetists (ASA) Physical Status Classification System.

    • Willing to complete pain assessments and clinic visits.

    • Additional inclusion criterion for randomization into the Double-Blind Phase: Subjects must experience postoperative pain intensity score ≥5 on a 0 to 10 Numerical Pain Rating Score (NPRS) more than 1 hour, and less than 9 hours after discontinuing the nerve block, and at least 30 minutes after the last ice pack has been removed (if used).

    Exclusion Criteria

    • Uncontrolled medical condition, serious intercurrent illness, clinically significant general health condition, or extenuating circumstance that may significantly decrease study compliance or otherwise preclude study participation

    • Clinically significant abnormal ECG at Screening

    • Gastric bypass surgery or gastric band

    • Previous abdominal surgery within the past year or history of abdominal adhesions, known or suspected paralytic ileus

    • History of any medical condition that would alter the absorption, distribution, metabolism or excretion of COV155 including but not limited to severe chronic diarrhea, chronic constipation, severe irritable bowel syndrome, or unexplained weight loss

    • History of severe bronchial asthma, hypercarbia, hypoxia or sleep apnea

    • Certain lab abnormalities

    • Addison's disease, benign prostatic hyperplasia, or kidney disease

    • Donated blood or blood components within 3 months prior to Screening or during study

    • Known allergy/hypersensitivity to any opioid analgesics, anesthetics, acetaminophen, non steroidal anti-inflammatory drugs (NSAIDs)

    • History of intolerance to short term opioid use

    • Unable to discontinue the use of prohibited medications or a history of substance or alcohol abuse within 2 years prior to Screening or a positive quantitative urine drug test at Screening

    • Positive for human immunodeficiency virus, hepatitis B or C

    • Dysphagia and/or cannot swallow study treatment whole

    • History of migraine or frequent headaches within the previous 2 years, seizures, or are currently taking anticonvulsants

    • Previously received COV155 in a clinical study, or undergone a bunionectomy within the last 3 months

    • Received any investigational drugs or devices within 4 weeks prior to Screening or during study

    • Active malignancy or history of malignancy within 2 years prior to Screening, other than completely eradicated cervical squamous cell carcinoma in situ or basal skin cancer

    • Currently taking neuroleptics or stable doses of a benzodiazepine

    • Other criteria as specified in the protocol

    • Additional exclusion criterion for randomization into the Double-Blind Phase: Have surgical complications that could compromise the safety of the subject or confound the results of the study.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Anaheim Clinical Trials Anaheim California United States 92801
    2 Lotus Clinical Research, LLC Pasadena California United States 91105
    3 Chesapeake Research Group, LLC Pasadena Maryland United States 21122
    4 Endeavor Clinical Trails, PA San Antonio Texas United States 78229
    5 Jean Brown Research, Inc. Salt Lake City Utah United States 84124

    Sponsors and Collaborators

    • Mallinckrodt

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Mallinckrodt
    ClinicalTrials.gov Identifier:
    NCT01743625
    Other Study ID Numbers:
    • COV15010232
    First Posted:
    Dec 6, 2012
    Last Update Posted:
    Oct 19, 2016
    Last Verified:
    Oct 1, 2016
    Additional relevant MeSH terms:
    Pain, Postoperative

    Study Results

    No Results Posted as of Oct 19, 2016